UBS Group
HUMA icon

UBS Group’s Humacyte HUMA Stock Holding History

UBS Group’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Buy
2,843,493
+61,423
+2% +$56.9K ﹤0.01% 5029
2026
Q1 		$1.69M Sell
2,782,070
-196,540
-7% -$204K ﹤0.01% 5115
2025
Q4 		$2.86M Buy
2,978,610
+976,275
+49% +$1.38M ﹤0.01% 4615
2025
Q3 		$3.48M Sell
2,002,335
-443,136
-18% -$868K ﹤0.01% 4414
2025
Q2 		$5.11M Buy
2,445,471
+1,019,616
+72% +$1.96M ﹤0.01% 3857
2025
Q1 		$2.43M Buy
1,425,855
+304,303
+27% +$1.14M ﹤0.01% 4537
2024
Q4 		$5.66M Buy
1,121,552
+937,539
+509% +$4.64M ﹤0.01% 3690
2024
Q3 		$1M Buy
184,013
+60,210
+49% +$397K ﹤0.01% 4655
2024
Q2 		$594K Buy
123,803
+29,618
+31% +$154K ﹤0.01% 4873
2024
Q1 		$293K Buy
94,185
+9,231
+11% +$31K ﹤0.01% 5586
2023
Q4 		$241K Buy
84,954
+51,538
+154% +$132K ﹤0.01% 5646
2023
Q3 		$97.9K Buy
33,416
+433
+1% +$1.43K ﹤0.01% 5841
2023
Q2 		$94.3K Buy
32,983
+12,399
+60% +$44.7K ﹤0.01% 6052
2023
Q1 		$63.6K Buy
20,584
+17,470
+561% +$49.7K ﹤0.01% 6265
2022
Q4 		$6.57K Sell
3,114
-6,713
-68% -$20.4K ﹤0.01% 9017
2022
Q3 		$32K Buy
9,827
+4,710
+92% +$18.1K ﹤0.01% 6796
2022
Q2 		$16K Buy
+5,117
New +$28.4K ﹤0.01% 7193
2022
Q1 		– Sell
-241,374
Closed -$1.75M – 10516
2021
Q4 		$1.75M Buy
241,374
+240,596
+30,925% +$2.38M ﹤0.01% 3856
2021
Q3 		$9K Buy
778
+237
+44% +$2.71K ﹤0.01% 8089
2021
Q2 		$6K Buy
+541
New +$5.57K ﹤0.01% 8444
2021
Q1 		– Sell
-335
Closed -$3K – 9202
2020
Q4 		$3K Buy
+335
New +$3.32K ﹤0.01% 8002

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UBS Group's HUMA Position: Q2 2026 in Review

UBS Group increased its Humacyte (HUMA) stake by 2.2% in Q2 2026, buying an estimated $56.9K and bringing the position to 2,843,493 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #5029.

UBS Group first reported a position in HUMA in Q4 2020 and has held it in 21 quarters since. The position peaked at $5.66M in Q4 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • UBS Group held 2,843,493 shares of Humacyte worth $2.22M as of Q2 2026.
  • UBS Group bought 61,423 Humacyte shares in Q2 2026, an estimated $56.9K.
  • Humacyte made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5029 holding.
  • UBS Group first reported a position in Humacyte in Q4 2020 and has held it in 21 quarters since.
  • UBS Group's Humacyte position peaked at $5.66M in Q4 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.